Learn more about HUMIRA Citrate-free
No citrate buffers,thinner needle, less pain
immediately following injection compared with the
HUMIRA 40 mg/0.8 mL presentation.2‡§
†Injection site pain immediately following injection as measured using a
0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA
40 mg/0.8 mL.
§needle size: 29 gauge vs 27 gauge
The recommended HUMIRA Citrate‑free initial dosing regimen for adults
The recommended HUMIRA Citrate‑free maintenance dosing regimen for adults
EOW=every other week; NDC=National Drug Code.
*Administered as one 80-mg injection.
Juvenile idiopathic arthritis or pediatric uveitis dosing
The recommended dose of HUMIRA for patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) or non-infectious intermediate, posterior and panuveitis is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with HUMIRA.
Dose & Corresponding NDC
Patients
(2 years of age and older)
10 kg (22 lbs) to < 15 kg(33 lbs)
10 mg
EOW
NDC: 0074-0817-02
HUMIRA Prefilled Syringe
Carton 10 mg/0.1 mL
Patients
(2 years of age and older)
15 kg (33 lbs) to <30 kg (66 lbs)
20 mg
EOW
NDC: 0074-0616-02
HUMIRA Prefilled Syringe
Carton 20 mg/0.2 mL
Patients
(2 years of age and older)
≥30 kg (66 lbs)
40 mg
EOW
NDC: 0074-0243-02
HUMIRA Prefilled Syringe
Carton 40 mg/0.4 mL
40 mg
EOW
NDC: 0074-0554-02
HUMIRA Pen Carton
40 mg/0.4 mL
HUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 years of age or in patients with a weight below 10 kg.
EOW=every other week; MTX=methotrexate; NDC=National Drug Code; NSAID=nonsteroidal anti-inflammatory drug
ADMINISTRATION CONSIDERATIONS1
HUMIRA is administered by subcutaneous (SC) injection: The first injection should be given under the supervision of a healthcare professional. A patient may self-inject HUMIRA after appropriate training and monitoring by a healthcare professional.
Prior to initiating HUMIRA and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection.
Instruct patients to rotate injection sites and not to inject into areas where the skin is tender, bruised, red, or hard.
In clinical trials, the most common adverse reaction was injection site reactions. 20% of patients treated with HUMIRA developed injection site reactions (erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving placebo. Most were mild and did not necessitate discontinuation.
Anaphylaxis or serious allergic reactions may occur.
Learn more about HUMIRA Citrate-free
No citrate buffers,thinner needle, less pain
immediately following injection compared with the
HUMIRA 40 mg/0.8 mL presentation.2‡§
†Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA
40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.
§needle size: 29 gauge vs 27 gauge